Current review of @entity16243 in the prevention of XXXX .

@entity1 @entity3974 @entity390 @entity16243 @entity750 @entity21 @entity10 @entity19473 @entity1209
@entity1209 ( @entity1209 ) are distressing and frequent adverse events of anesthesia and surgery. @entity750 receptor antagonists (SRAs), including @entity3974 , granisetron, @entity19473 , dolasetron, and @entity16243 , effectively decrease the incidence of @entity1209 . Among these SRAs, @entity16243 is the most effective antiemetic for the prophylaxis against @entity1209 in terms of the inhibitory potency, binding rate, and stabilizing its pharmacological activity. This review article focused on the efficacy of @entity16243 for preventing @entity1209 (POV) in @entity1 . Because of young age of pediatric @entity1 , @entity390 was not assessed a separate entity. MEDLINE (PubMED) and EMBASE (January 1990 - September 2010) were searched for randomized, double-blind, (placebo-controlled), studies (written in English) of @entity16243 for preventing @entity1209 in adults and POV in @entity1 . The incidence of @entity1209 during 0-24 h after anesthesia was less in @entity1 receiving @entity16243 0.3 mg than in those receiving placebo, in adults undergoing gynecologic surgery, dilatation and curettage, laparoscopic cholecystectomy, middle ear surgery, thyroidectomy, and total hip/knee replacement. The incidence of POV during 0-24 h after anesthesia was less in pediatric @entity1 receiving @entity16243 6 mcg kg(-1) than in those receiving placebo, in @entity1 undergoing strabismus surgery and tonsillectomy. In adults, the most commonly reported adverse effect was @entity10 (5-20%). In @entity1 , clinically serious adverse events, such as excessive sedation and @entity21 , were not observed. Prophylactic therapy with @entity16243 is effective for preventing @entity1209 in adults and POV in @entity1 without clinically serious adverse effects.
